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Ovarian cancers are still the most lethal gynecologic malignancy. As a novel strategy against this poor
outcome cytotoxic alterations induced by a pro-oxidant treatment on human ovarian endometrioid
carcinoma (MDAH 2774) cells are revisited by using light, scanning and transmission electron micro-
scopy. A series of sequential and concomitant cellular and organelle injuries induced by ascorbate:
menadione combination (VC: VK3) or Apatone
® is emphasized. This adjuvant or treatment is able to kill
majority of these tumor cells through ‘autoschizic cell death’, a mode of cell death different than
apoptosis. Autoschizic cell death is signiﬁcant after a short period of treatment to decrease the ovarian
tumor cell population through induced injuries that proceed from membranes to most organelles:
karyolysis with nucleolar segregation and fragmentation, autophagy of mitochondria, lysosome and
other organelles as well as cytoskeletal defects. The cytoskeletal damages are evidenced by morphology
changes that included auto- or self-excised pieces of cytoplasm lacking organelles apparently facilitated
by grouping of vacuolated endoplasm. These results obtained against this endometrioid ovary cell line
are comforted by other studies using Apatone® against other carcinomas in vitro and in vivo. Altogether
these reports support Apatone® as a new drug that can favorably be used as a novel potent, safe, and
inexpensive clinical adjuvant or treatment against ovarian cancers.
© 2015 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In the United States alone, the number of estimated new ovarian
cancer cases for 2015 is estimated as 21,290with an outcome of 44%
survival, i.e. an estimated 14,180 deaths [1]. Even though this ﬁgure
represents about 3% of all new female cancer cases which is lower
than the marked incidence 12 years ago [2], the current statistics
have remained similar during the past 45 years. It is also noted that
ovarian cancer is more common in North America and Europe than
in Africa and Asia [3e6].
Due to its late detection, and lack of clear screening guidelines,l Sciences, St George's Uni-
ife Sciences, Drill Hall 013,
.
is an open access article under thovarian carcinomas are the most lethal malignancies. Its poor sur-
vival rate can be attributed to vague, non-speciﬁc clinical signs and
markers signaling the disease. In addition, its slow and insidious
peritoneal invasiveness that is difﬁcult to assess with only by a few
routine, clinical markers. Poor ovarian carcinomas' treatment out-
comes are caused by detection at an advanced stage; after install-
ment of the malignant cells on the peritoneal surfaces of one or
more organs, very similarly to what is found prostate tumors [7].
Additionally, these cancers spread early through lymphatics and it
is only long-surviving patients where haematogenous, metastatic
spreads result in bone marrow or brain inﬁltrations [8]. The 5-year
survival rate of all ovarian cancers is estimated to be around 30%
after treatment [9]. This rate has not improved for the last 35 years
[10,11]. Thus, ovarian cancer is truly the leading cause of death
amongwomenwith the traditional gynecologicmalignancies in the
United States [12] and elsewhere [6]. Furthermore, chemotherapye CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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because of its chemo-resistance.
This basic science report complements previous reports despite
the development of new markers and more speciﬁc treatment
[13e21]. Morphology, histochemistry and biochemistry data from
Apatone® treatment of MDAH2774 human endometrioid ovarian
carcinoma cells may be safely translated into clinics as a comple-
mentary, alternative medical adjuvant or even primary treatment
in early detection.
This report again brings credence to support the usage in clinics
of an innovative, potent, safe and inexpensive treatment, made
from a combined ascorbate: menadione sulﬁte, named Apatone®.
This drug can become an adjuvant to surgical, irradiation and/or
chemotherapeutic treatment against ovarian carcinomas, related
perineal and peritoneal malignancies. Alone Apatone® kills tumor
cells efﬁciently not only in vitro but also tumors bearing in vivo
xenotransplants [21e23]. In combination with irradiation, it offers
an attractive complementary chemotherapeutic therapy that leaves
normal cells and other organ-systems unaffected by the treatment
[21,22,24].
2. Materials and methods
2.1. Cell line
Human ovarian carcinoma cells (MDAH 2774), purchased from
the American Type Culture Collection (ATCC, Rockville, MD), orig-
inate from the ascite's ﬂuid of a patient with endometrioid ovarian
carcinoma who did not received chemotherapy or radiation prior
the collection of cancer cells. Characterized at the MD Anderson
Hospital and Tumor Institute (Houston, TX), these cells were found
to be hypotriploid [25]. This cell line was cultured in Eagle's Mini-
mum Essential Medium (MEM; Gibco Labs, Grand Island, NY)
supplemented with 10% heat-inactivated fetal bovine serum (FBS;
Gibco) and 50 mg/ml gentamicin sulfate (Sigma Chem. Co, St Louis,
MO). All incubations, treatments and microtiter tetrazolium (MTT)
assays were performed at 37 C and with 5% CO2 unless other
conditions are stated.
2.2. Test solutions
Ascorbate sodium (Vitamin C or VC) and menadione bisulﬁte
(VK3), purchased from Sigma Chemical Company (St. Louis, MO),
were used for the cytotoxicity experiments. The vitamins were
dissolved in phosphate-buffered saline (PBS) to create 8000 mMVC,
500 mM VK3 and 8000 mM VC: 80 mM VK3 test solutions. Both vi-
tamins were dissolved in culture medium to create test solutions
with ﬁnal concentrations of 2032 mM VC, 20.32 mM VK3, and
2032 mM VC: 20.32 mM VK3. To prevent photo-degradation of the
vitamins, vitamin solution preparation and all experiments were
performed in a darkened laminar ﬂow hood.
2.3. Cell culture
Titer dishes were seeded with 1.0  106 MDAH cells; they were
allowed to attach and spread for 24 h at 37 C. Following exposure
to each vitamin alone and in combination, cells were harvested at
one-, two-, and three-hour intervals and processed for TEM ob-
servations. In this report tumor cells Sham- or Control-treatedwere
compared with the combined VC: VK3-treated cells.
2.4. Cytotoxicity assay
The cytotoxicity assay was performed using the micro-
tetrazolium [MTT 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-diphenyl tetrazolium bromide] assay as described previously [23].
After vitamin treatment and the incubation period, cytotoxicity was
evaluated using the MTT assay. Following linear regression, the line
of best ﬁt was determined and the 50% cytotoxic dose (CD50) was
calculated.2.5. Histochemistry
Circular coverslips were seeded with 105 MDAH cells and
incubated for 24 h at 37 C. The cells were then overlaid for one-,
two-, and three-hour with media containing only media (Sham-
treated group) and their combination as VC: VK3. All cells were
washed twice with PBS, ﬁxed for 1 h in formalin at room temper-
ature and then washed three times for 5 min/wash with PBS.
Feulgen DNA staining was accomplished according to Pearse [26]
without other counterstaining. After rinsing, dehydration in
graded ethanol, the preparations were cleared in xylene before
mounted in synthetic DPX medium. Control slides that were not
hydrolyzed nor treated by Schiff after hydrolysis did not provide
staining of the chromosomes of dividing cells nor the DNA. All
chemicals (at least 99% purity) were prepared and used from the
same containers and originated from Fisher Scientiﬁc Co (Pitts-
burgh PA). Staining was accomplished simultaneously for both
cover slips with treated cell groups to avoid batch speciﬁc varia-
tions in DNA degraded staining [27]. All dehydration and prepara-
tions were also made at the same time and in the same hood with
light intensity and temperature (17e18 C). After a 2-h setting to
allow polymerization of mounting medium and to prevent light
defects, all sections were stored in the dark at 4 C overnight and
examined the next day morning at the same time. Micrographs
were taken under immersion oil with an Olympus BX51 photo-
microscope (Olympus America, Melville, NY). All micrographs were
printed from Kodak Ektachrome 64T reversal ﬁlm (Kodak, Eastman
Kodak Co, Rochester, NY) and prints were made from slides by
using same batch of paper and photographic reagents.2.6. Cell measurements
Cell size was determined using the orthogonal diameters
method of Song et al. [28]. Brieﬂy, the length was deﬁned as the
largest diameter, while the width was obtained by measuring the
diameter of the cell orthogonally to the length. At least 100 cells
were measured for each treatment group.2.7. Densitometry of Feulgen staining data and statistical analysis
Optic densitometry of Feulgen stained samples was obtained
and copied from Gilloteaux and collaborators [19]: nuclei observed
in about 36 ﬁelds of color micrographs from each Sham and VC:
VK3-treated MDAH cells. The measurements of optical reﬂectance
units were averaged in a histogramwith standard error of themean
(s. e. m.). Repeatable measurements were able to be obtained
within 1% of each reading. Following one-, two- and three-hour
vitamin exposures, DNA degradation with the VC: VK3 combina-
tion was assessed by measuring decreased intensity of Feulgen
staining of tumor cell DNA compared with those obtained with
Sham treated cells. The other measurements reported previously
were made after either VC or VK3 treatment alone and were
compared with the ones reported here [19]. Two-way analysis of
variance was used in which both vitamin treatments were inter-
acted. The single-degree-of-freedom interaction test of the effect of
the combination of VC and VK3 followed directly from this two-
factor model.
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Total DNA was extracted after each treatment from 4.106 MDAH
cells, run on 0.6% agarose gel treated according to [28] and stained
with ethidium bromide as described in Ref. [19].
2.9. Scanning electron microscopy (SEM)
After each treatment, cells were washed with PBS and ﬁxed in
2.5% glutaraldehyde phosphate buffered solution with 0.13 M su-
crose; pH 7.35 or PBS for 10 min at room temperature according to
[29]. After 2  10 min washes in sucrose-phosphate buffer, cells
were post ﬁxed in a 1% OsO4 aqueous solution for 30 min at room
temperature. Cells were then washed twice for 10 min in the same
buffered solution before they were dehydrated and critical-point
dried in a E-300 BioRad unit (Cambridge, MA). All samples were
sputter-coated with gold-palladium to a thickness of 1.0e1.5 nm.
Cells were then examined in a Hitachi S-570 SEM (Mountain View,
CA) at 12e13 kV emission accelerating voltage and at a distance of
12e15 mm from the cells. Micrographs were collected with
Polaroid type 55 ﬁlms. Samples were viewed at 0 and at 35e40 tilt
angles to obtain polar (cell size measurements) and proﬁle views of
the cells.
2.10. Transmission electron microscopy (TEM)
MDAH 2774 cells grown as a monolayer were exposed either to
PBS alone or the VC: VK3 combination for 1 h, then washed in PBS
buffer, harvested and allowed to sediment by slow centrifugation
(450e500 rev/min). After removal of the supernatant, the treated
cells were ﬁxed in 2.5% phosphate-buffered glutaraldehyde solu-
tion with 0.13 M sucrose-phosphate, pH 7.35 for 30 min at room
temperature in 2 mm3 microfuge tubes [29]. After two 10-min
washes in sucrose-phosphate buffer and gentle sedimentation of
a formed pellet of cells for each treatment, 30 min post ﬁxationwas
done in 1% osmium tetroxide aqueous solution, under a fume hood,
and at room temperature. Pellets contrasted by this post ﬁxation
were washed twice for 10 min in the same buffered solution before
dehydration and processing into PolyBed epoxy resin (Polysciences,
Warrington, PA). From each blocks, one-mm thick sections were
then stained in toluidine blue to select areas for ultramicrotomy.
These sections were collected on 75- and 100-mesh hexagonal
copper grids (SPI, West Chester, PA), stained in uranyl acetate and
lead citrate, and examined in a Zeiss EM-10 TEM (Carl Zeiss,
Thornwood, NY). The digitized images were obtained using an
analySIS 2.1 software system © (Soft Imaging System GmbH,
Lakewood, CO and Münster, Germany) in the Pathology Depart-
ment of the Children's Hospital Medical Center of Akron, OH.
3. Results
Observations made with morphological techniques (SEM, LM
and TEM) are described in the order the investigators collected data
and complement those submitted in previous publications. This
report emphasizes data comparing Sham-treatment against the VC:
VK3 combined treatment (Apatone®) to demonstrate that the
cytotoxic injuries kills ovarian endometrioid carcinoma cells,
further supporting its translating clinical potential.
3.1. SEM views
A general aspect of the preparations collected with this tech-
nique showed an even distribution of cells on the cultivation sup-
port with spaces caused by the arrest of culture long before cells
attain their conﬂuence. At ﬁrst glimpse, MDAH cells distribute intoa homogeneous population of small sized cells, ovoid to spherical
and with a slight elongated morphology. They can ﬂatten and
display a poor contrast against their growing support. Their nuclear
zone is elevated and often present with one elongated extension
that resembles a cytoneme, giving them an oblong, stretched pro-
ﬁle. Some cells can be noted with a large spherical proﬁle compared
to the elongated ones as they likely correspond to being less motile
as they prepare to or have undergone replication. Other scant but
obvious ‘double’ or ‘twin’ cells, still closely adjacent, can be found
among this population and seem to corroborate this latter inter-
pretation (Fig. 1A). Finally, Fig. 1C, a higher magniﬁcation of a ﬁeld
of Fig. 1A, veriﬁes the general aspects of the Sham cells as they
display upper cell surfaces loosely wrinkled that could be referred
with a ‘peau d’ orange’ texture with a few poorly preserved
microvilli but bear a radiating and diffuse array of delicate ﬁlopodia
(1e3 mm long) along their edges. In general, cells are ovoid to round
and vary from 25 to 35 mm in length, 15e25 mm in width and
sometime can show a single, uropod-like and short lamellipodia
issued from their surfaces of culture support (Fig. 1AeB). In Fig. 1A
tumor cells appear evenly spaced with a few overlapping cells
suggesting some limited cell contact inhibition likely due to the
culture time that was stopped when the cells were still separated
from one another. Arising from a few cells one can notice short to
long uropod- or cytoneme-like extensions running toward other
cells. In the higher magniﬁcation (Fig 1B), several cells out of the
previous Fig. 1A reveal their evenly textured surfaces, somewhat
wrinkled like orange skin caused by appearing short digitations or
short lamellipodia being ﬂattened as they cover the upper surfaces
of the cultivation support. They display similar size compared to
those viewed on the basal aspects, revealing short size ranging
from 0.5 to 1.0 mm in length. Tenuous ﬁlopodia (1e3 mm in length)
can also be seen sprouting out of these lamellipodia in a loose but
evenly distributed fan-like irradiated manner. Using light micro-
scopy, most 1 mm-thick epoxy sections of pellets obtained after
treatment (Fig. 2AeB) allowed complementary aspects with the
morphology obtained with the SEM micrographs (Tables 1 and 2).
3.2. LM observations
3.2.1. Control or sham-treated MDAH 2774 cells
Using 1 mm-thick sections stained with Toluidine blue LM
samples of culture areas of Sham MDAH 2774 tumor cells reveal
some diversity in staining characteristics because diverse blue-to-
purplish contrast appear. Sham cell population of MDAH 2774 is
uninucleate, show high replication activity and growth in vitro. A
few, rare multinucleate cells can be seen, as noted earlier (Gillo-
teaux et al., 2004). One has noted that most pale-stained cells in the
micrographs of the pane in Fig. 2 are captured undergoing pre-
prophase to anaphase stages and some obvious mitotic stages,
eventually displaying chromosomes while those with highest
contrast are in interphase. The interphase cells displayed a typical
morphology characteristic of poorly differentiated tumor cells,
showing a high nuclear: cytoplasmic ratio. Their shape and nuclei
are sub-spherical and all of them displayed a large, prominent
nucleolus, sometimes with a branching aspect as one can detect
more than one sections of the nucleolar body (Fig. 2B). Similarly, in
Fig. 4A and B, higher magniﬁcations illustrate their surfaces that are
not smooth and in most cells discrete and hairy aspects seem to
conﬁrm the many small lamellipodia better revealed with SEM
technique. Furthermore, some uropodial-like extensions can be
infrequently noted, such as in the insert of Fig. 4 A. It is noteworthy
indicating that Sham cells reveal a densely contrasted cytoplasm. In
addition, one can seldom observe tiny cell debris (less than 1.0 mm).
Among the Sham cells in culture, entosis can be seldom observed as
a cannibalistic activity where old or dying cells are captured and
Fig. 1. A-D. SEM views of 1 h Sham-treated human ovarian carcinoma (MDAH 2774) cells on culture support. In A, a low magniﬁcation view of the evenly-distributed population of
the pleomorphic cells adhering to their culture substratum. B, C and D show tumor cells at progressively higher magniﬁcations demonstrating a surface, smoothly wrinkled and
from their basal aspects sprout a few, short lamellipodia out of which at their basal aspects fromwhich sprout numerous delicate long and short irregular ﬁlopodia sprouting out of
lamellipodia. Scale in A is 50 mm, in B and C is 10 mm and in D is 1 mm.
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3.2.2. VC: VK3-treated MDAH 2774 cells
A quick survey of several ﬁelds of view clearly veriﬁes that these
treated MDAH cells remain with obvious large, empty spaces of an
outlived population of cells when compared with Sham-treated
cells. These surviving cells are mainly elongated cells, appearing
almost as ﬁbroblast-like, with a spherical to oblong oval shape
nuclei. The cells show long, tapered edges contacting one another
or not with edges presenting crawling lamellipodia out of which
numerous ﬁlopodia (1.0e3.0 mm) are issued. The cells rarely appear
in clusters and, among them, a few spherical ones, often distorted,
leave intercellular spaces littered by scattered corpses or cell debris
(Fig. 1B). Along and adjacent to their cell surface a few, self-excised,
cytoplasmic pieces with their delicate connections (<1.0 mmwide)
can be found as contrasting from the background (Fig 3C and
insert). The spherical cell type resembles those found in Sham cells
but less contrasted and often possess several bulging or bursting
blebs, again suggestive of cells undergoing self-cuts as shown in
most micrographic ﬁelds of view (Fig. 3B and C). A fewmultinucleate cells, with 2e9 nuclei, stand by their enormous size
among the populated preparation (Fig. 3A and C).
Endometrioid tumor cells in selected high magniﬁed LM views
of one-mm thick epoxy sections stained by toluidine blue clearly
conﬁrm the pleiomorphic alterations caused by the pro-oxidant
treatment (Figs. 3 AeC and 5 AeB). Most spherical cells become
elongated and distorted, with tapered aspect at one or both ends
and often include extensions resembling cytonemes as lamellipo-
dia. These structures are uniformly contrasted by a light to deep
purpleeviolet hue according to their accumulated content in
glycogen and, especially, in ribonucleoproteins. At ﬁrst glance, cells
appear difﬁcult to size but through measurements they are smaller
than the Sham cells with diameters ranging from less than 5e12 mm
resulting in a calculated average diameter of 14.7 ± 3.8 mm after 1 h
treatment that decreased to 12.8 ± 2.4 mm after 2-h treatment and
to approximately 10.8 ± 1.3 mm after 3-h treatment. Some large
cells display vacuolated cytoplasm and blisters while most undergo
cytoplasmic self-cuts detected throughout the ﬁelds of view. Self-
cuts are suggested by cells that appear spherical with their nu-
cleus rimmed by a continuous but narrow layer of heterochromatin
Fig. 2. AeB. Light microscope view of 1 h Sham treated human ovarian carcinoma
(MDAH 2774) cells; toluidine blue stained epoxy 1 mm-thick sections. Most cells appear
round cells with large spherical and indented nuclei; stages of mitosis are apparent in
the palest cells. In B, a peculiar, multi-nucleated cell with spherical nucleoli in each
nucleus and a closely adjacent, small cell with same contrast can be found. In C, ex-
amples of pale cells (labeled ‘ * ’) undergoing pro-metaphase of cell cycle; a curved
arrow marks an uropod and at its left a twin-cell is preserved in telophase. In D, a small
arrow points to entosis in progress. The scale in A is 50 mm, in B is 10 mm.
Table 1
Diameters of MDAH 2774 cells and cell debris (in mm).
Control VC þ VK3
Length 25 e 35 9 e 15
Width 15 e 20 5 e 12
Cell debris 0.1 e 0.5 1.5 e 6.5
Measurements were takenwith polar views of SEM andmade on at least 100 cells or
pieces of cell debris.
Table 2
Percent of population of MDAH 2774 undergoing mitotic replication and cell death
after each treatment.
Treatment Mitosis Type of cell deaths
Oncosis Apoptosis Autoschizis
Control (n ¼ 541) 7.2 ± 2.6a 1.3 ± 0.6 3.5 ± 0.6 2.7 ± 0.5
Vitamin C þ K3 (n ¼ 717) 7.0 ± 2.1b 1.9 ± 0.2 3.0 ± 0.5 43.0 ± 6.5
a All stages of mitosis were detected.
b Only Prophase or Metaphase stages of mitosis were detected. The number of
mitoses and number of each type of cell death were counted from at least 3 sets of
thick sections and expressed as the average ± the standard error of the mean.
Fig. 3. AeC. LM views of 1 h VC:VK3 -treated human ovarian carcinoma (MDAH 2774)
cells; 1-mm thick epoxy section stained by toluidine blue. In A: cells show great
pleiomorphism oblong and distorted cells and debris of cells in their intercellular
spaces. Only a few spherical cells remain and those left are often much smaller than
the Sham-treated cells. In B and C: Magniﬁed views display most tumor cells surfaces
show uneven texture and distorted nuclei and bubbly, vacuolated cytoplasm, making
them less contrasted than Sham-treated cells. Small to enormous, round to conical,
chubby blisters or blebs (curved arrows) appear along each cell suggesting alterations
of the superﬁcial and deep cytoskeleton. As a result, many debris litter the intercellular
spaces (thick arrow in C). The scale is 50 mm in A, 10 mm in B in C.
J. Gilloteaux et al. / Translational Research in Anatomy 1 (2015) 25e39 29and a narrow perikaryon that hangs on a small to large, uniformly
pinkish-blue to dark purple cytoplasmic piece that appears to also
self-cut (i.e. insert of and in Fig 3C and star-labeled in Fig. 5A and B).
Among the cells treated and collected, numerous 0.5e6.5 mm
diameter cell debris can be noticed and viewed in the intercellular
spaces. In many cells the nucleoplasm appears peculiarly pale pink
J. Gilloteaux et al. / Translational Research in Anatomy 1 (2015) 25e3930with a ‘milky’ hue view with peripheral heterochromatin patches
displayed as thickened curved rims along the inner membrane. In
other treated cells, the quasi entire heterochromatin seems
extracted out of the nucleus, leaving tiny peripheral bits (Figs. 3
BeC, 5 AeB). Only very rarely treated cells display a huge spher-
ical and pyknotic nuclear mass that precedes necrosis (Fig 5AeB).
Many of the treated cells also reveal distorted nuclei indicative of
cytoskeleton alterations. Other nuclear changes show nucleoli
reduced to their compacted granular component into either one
huge round to irregularly oblong contrasted mass or fragments
often reduced into a minute spherical dot less than 0.5 mm in
diameter (Figs. 3 BeC, 5 AeB). In many cases the nucleoli that
remain or eventually fragment into irregularly oblong or spherical
bodies can appear in the intercellular spaces after cell demise
among the other remaining injured, poorly surviving cells. Among
the collected population, only a few, rare treated cells undergo cell
death through apoptosis as indicated by their nucleus with highly
contrasted masses (arrowed in Fig 5A and B).
3.3. Histochemistry
3.3.1. Feulgen stain
This technique veriﬁes that DNA degraded through karyolysis
caused by the combined VC: VK3 treatment (Fig 6). One-, two and
three-hour duration Sham (CONT-treatment tumor cells) show
intact and heavy stained chromatin. The same pane compares an
adjacent photomontage of samples of tumor cells after one-, two-
and three-hour duration treatment with VC: VK3 that shows a
signiﬁcant decrease, not only of cell size and shape, but also a
signiﬁcant diminished nuclear contrast indicating a signiﬁcant
depletion in DNA compared to Sham cells, as noted in the histo-
gram of Fig. 7. In addition, Fig. 8 depicts the data obtained with one
agarose gel electrophoresis after 3-h treatment by VC: VK3-MDAH
cells. It displays a smear pattern when compared with intact ﬁ-
broblasts suggesting a DNA fragmentation that is certainly different
than the laddering degradation of DNA found in apoptosis. After
VC: VK3 treatments, the Feulgen stain demonstrates a signiﬁcant
decrease in the intensity of the staining contrast suggestive of
increased karyolytic damages in accordance to the duration of
treatment (Figs. 6e7). This prompted repetitious DNA total ex-
tractions and viewing them with gel electrophoresis.
3.3.2. DNA gel electrophoresis
The possibility that total DNA degraded in MDAH cells occurred
out of treatment is unlikely since human foreskin ﬁbroblasts
(MHRF) exposed to both Sham-Control and after 4-h treatment
with the vitamin combination did not show such damages. DNA
extracted and resolved electrophoretically shown in Fig. 8 dem-
onstrates that lanes 2 and 3 respectively contain the DNA of VC:
VK3-treated (VCK) and Sham-treated (CNT) MHRF cells. DNA from
the Sham-treated MHRF cells appears as a single high molecular
weight band slightly below the well in which it was loaded.
Conversely, DNA from VC: VK3-treated MHRF cells appear as a low
molecular weight smear at or below 200 bases. On the opposite
side, DNA extracted from sham-treated MDAH cells appears as aFig. 4. A and B. LM views of human endometrioid carcinoma (MDAH 2774), 1-mm thick
epoxy section stained by toluidine blue, 2-h after Sham-treatment. All cells display
spherical aspects with surfaces covered by short ‘hairy’ microvillar-like extensions.
Some cells show an uropod-like (curved arrow in insert of A) and eventually under-
going cell cycle (also in insert of A) as noted by harboring chromosomes either in
prophase or pale and in pre-metaphase (in A and B). Large vacuole-like areas made of
accumulated glycogen and fatty deposits along with few cell blebs or debris can be
seen (*). Surprisingly, one entosis phenomenon is captured in A (small arrow). Scales
are 10 mm.
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it was loaded, while the DNA from vitamin treated MDAH cells
exhibits a spread pattern. The absence of laddering in the vitamin-
treated lanes with DNA damages strongly suggests that VC: VK3
treatment induced cell death through a different process than in
classic apoptosis.
3.3.3. Densitometry measurements
In order to quantify the changes in staining patterns that sug-
gested karyolysis wherein signiﬁcant DNA degradation was ex-
pected, we measured differences in light absorption between
treatments (Fig 8). Measurements of the DNA in nuclei of the
treatedMDAH cells as displayedweremade only after a 3-h vitamin
exposure due to the abundance of cell death, detachment and
disintegration in longer vitamin exposures. As shown in the his-
togram of Fig. 8, DNA staining intensity of Sham-treated (CONT
cells) is 32.5 ± 1.127. The DNA staining intensity values for VC and
VK3 alone are 21.6 ± 1.127 and 32.6 ± 1.127 [14,18], while the DNA
staining intensity of the vitamin combination is 15.6 ± 1.127. Notice
that the average DNA level following VK3 appears to look similar to
the Sham group. By contrast, DNA level following VC or VC: VK3
treatment is signiﬁcantly lower than in the control group
(p < 0.0001). In addition, DNA intensity level following VC: VK3
treatment is signiﬁcantly different from the DNA intensity level
only following the VC treatment (P < 0.03). The standard error
values are all identical because they were based on a pooled vari-
ance estimate (Fig. 8).
3.4. TEM aspects: (Figs. 9 and 10AeG)
Control or Sham-treated MDAH 2774 cells always display a
spherical morphology that ranged between 20 and 35 mm in
diameter; they are covered by small microvilli-like ﬁlopodia,
ranging between 1 and 1.5 mm, often with an unusual bifurcate
aspect (Fig 9). These endometrioid cells are poorly differentiated
with a typical high nuclear: cytoplasm ratio and contain a large
nucleolus. With TEM, the large nuclei often shows ovoid to sub-
spherical shape with a deep indent as a narrow groove that
makes the organelle to appear ‘coffee bean’ in morphology. This is
often detected with thick views or sections of histology ﬁelds of
view. Because of its large size, only the edge of the intranuclear
branching structure of the nucleolus is usually detected. The overall
nucleoplasm is euchromatic with the delicate thickening of the
inner nuclear membrane being clearly interrupted by nuclear
pores. The perikaryal, narrow cytoplasm is ﬁlled by innumerable
ribonucleoprotein granules with patches of glycogen and a few
fatty droplets. A number of rough and smooth endoplasmic
cisternae are distributed throughout the remaining cytoplasm.
Some MDAH2774 tumor cells defects observed with LM after
treatment by the combined, pro-oxidant vitamins (Apatone®) are
shown in the pane of Fig. 10AeG. There a selected series of mi-
crographs that demonstrates some of the ongoing auto- or self-
excising (autoschizic) processes and degradations at the level of
the nucleus, other organelles and cytoskeleton. The damages
observed with the vitamin combination are exacerbated and occur
more rapidly (1 h vs. 3 h) than with an individual vitaminFig. 5. A and B. LM views of human endometrioid carcinoma (MDAH 2774), 1-mm thick
epoxy section stained by toluidine blue, 2-h after VC: VK3 treatment. Most cells show
elongated and distorted shapes along with their nuclei. If spherical, the nucleus appear
empty of chromatin or with remnants of heterochromatin as patches on the inner
nuclear membrane. Most nucleoli are resolved as either enormous, condensed
spherical or fragmented masses of fragments. Most cells display ongoing self-excisions
that contain contrasted ribonucleoprotein material and their debris that result (*). A
few, rare cells undergo apoptosis (arrows). Scales are 10 mm.
Fig. 6. Feulgen-stained Sham-and VC: VK3 -treated ovarian (MDAH2774) endometroid
carcinoma cells. The gallery of micrographs contains columns (period of treatments: 1-
, 2-hr, and 3-hr) and rows (type of treatments: Sham (CONT) and combined VC-VK3. In
all the micrographs, “n” represent the nucleus. Note that chromosomes block in
metaphase are clearly viewed in the 2-h treatment insert. Small curved arrows mark
selected examples of cytoplasmic self-excisions. The scale indicated as 10 mm is for all
the illustrations of Sham and treated cells. Reprint from part from our published work
[18].
Fig. 7. Agarose gel electrophoresis of total DNA from Sham-treated and VC: VK3
treated human ﬁbroblasts (MHRF) and ovarian endometroid (MDAH 2774) cells. Lane 1
contains molecular weight markers. Lane 2 contains DNA from VC: VK3- MHRF treated
cells (VCK) while lane 3 contains DNA from Sham-treated MHRF cells (CNT). Lane 4
contains DNA from VC: VK3-treated MDAH cells (VCK) while lane 5 contains DNA from
Sham-treated MDAH cells (CNT). By permission [18].
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accumulated with nucleolar changes involving chromatin illustrate
that the heterochromatin is roughly plastered along the inner
nuclear membrane (seen with LM in Fig. 3A). Additionally, thecondensation of the nucleolus results in ribonucleoprotein masses
where chromatin can be seen in some sort of clouds-like pattern
afar of them as depicted in Figs. 3C and 5AeB. At the same time, a
diminished cell size caused by auto-cuts (or autoschizis) veriﬁes
karyorrhexis while segregating a large piece of cytoplasm to further
excisions is displayed in Fig. 10AeG. Throughout the treated cells
most mitochondria appear swollen with a ﬁne granular content
amongst one or more osmiophilic clumped membrane debris in
their matrices. Most other organelles are unable to be resolved as
they were degraded as small to large vacuoles where only
some large or small osmiophilic bodies can be resolved throughout
the cytoplasm, clumped along and in the perikaryal areas (Fig. 10A
and C).
Accumulated vacuoles of the swollen SER-RER assemble in the
perikaryon where other damaged organelles group or align along
the most contrasted peripheral zones. They appear to assume some
sort of self-excision in these uniformly contrasted pieces of cyto-
plasm loaded with ribonucleoproteins and glycogen. These self- or
auto-cuts contribute to the tumor cell excisions, hence diminishing
their size. An example of elongated cell through cytoskeletal
damage is best exempliﬁed in Fig. 10DeGwhere the insert reveals a
constellation of gathered vacuolated bodies that likely undertake
the excising cell process we have previously named autoschizis.
Fig. 8. The histogram summarizes the relative DNA content of Sham- and VC:VK3-
treated endometrioid (MDAH 2774) cells. The bars correspond to the calculated av-
erages of the densitometric measurements of the reﬂectance intensity collected from
the microscopic preparations as some selected ﬁelds of view are illustrated in Fig. 7.
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4.1. The cell line
MDAH 2774 is an endometrioid ovarian adenocarcinoma cell
line developed from ascite cells from a female patient withFig. 9. TEM view of a small Sham-treated endometrioid (MDAH 2774) cell depicting its
large coffee bean-shaped nucleus and its small cytoplasm crowded by electron densely
contrasted ribonucleoproteins and containing a few fatty deposits and a few con-
trasted round lysosomes can be noticed in the lower cell area. A branching nucleolus
appears in this section. Scale equals 5 mm.endometrioid ovarian cancer; it forms tumors in nude mice with
triploidy of 1, 2, 3, 6, 11, 12, 16, X, and a single copy or monosomy of
number 17 and number 21 chromosomes. Chromosome 5 was
triploid in 6 out of 7 cells while the remaining chromosomes
showed apparent random variation in the number of copies with a
general trend toward triploidy [25].
4.2. Endometrioid carcinoma of the ovary
Even though the etiology of ovarian cancers is poorly under-
stood reproductive hormones are likely involved estrogens and
metabolites, especially estrone, as well as exogenous hormones or
factors and may include progestins or factors, including replace-
ment therapies and infertility treatments can be involved in the
ovarian cancers as supported by studies in animals [31e33].
Endometrioid carcinoma cells of the ovary have been described
by several authors as endometrium-like (for example, but not
limited to [34e42]). A classic interpretation describes that some
serous endometrioid tumors, usually serous in nature, may have an
entwined and dualistic origin: (i) with the germinal epithelium (i.e.
the main ovarian mesothelial surface epithelium in many cases)
[34,43] and (ii) with the endometrial deposits or implants as the
appellation ‘endometrioid’ suggests [43e49]. This tumor type is
often associatedwith carcinoma of the uterine corpus that has been
reported as high as 20% of cases [34,43,50,51]. Other endometrioid
tumors can arise with papillomavirus infection and decreased
expression of p16 out of hypermethylation of the promoter or the
gene [52,53]. A constant ﬁnding of laminin a1 in basement mem-
brane, not found in serous or mucinous ovarian type, could be
marker of this endometrioid tumor type while a lack of laminin a2
and collagen type VII immunoreactivity were also noted in endo-
metrioid carcinomas of the ovary [54]. Finally, another study
showed that endometrioid carcinomas were likely vimentin posi-
tive and carcinoembryonic antigen positive contrarily to the
endocervical endometrioid that has these markers negative [55].
Additional defects incurred caused by genome alterations in com-
mon with other carcinomas, such as E-cadherin changes [56e58].
Endometrioid tumor can be highly aggressive, usually present in
postmenopausal age [59], and found in advanced stages. They
comprise of serous, high-grade benign cancer cells but can become
easily malignant due to their epigenetic mutations to acquire
Mϋllerian characteristics with cell shape modiﬁcations, appearance
of E-cadherin, secretory mucins (MUC1, MUC2, MUC3 and MUC4)
and CA125 (such as [41,60,61]). Using DNA microarrays for assess-
ing ovarian cancer gene expression 150 out of 35,000 genes asso-
ciated with ovarian defects with a highest frequency in TP53
mutation along with other genetic proﬁling [62]. Its subtypes have
an associative plethora of 422 gene mosaic mutations [63,64]. In
addition, hormones, growth factors and cytokines are involved in
initiating and progressing growth along with some hereditary
predisposition that can play an important role (review in Ref. [41]).
Within the most recent survey genetic alterations can cause 10% of
all ovarian cancers [5]. In all, ovarian endometrioid tumors such as
MDAH 2774 can include e but are not limited to e gene defects
TP53, Stat 3, ARIDIA, BRCA1, BRCA2, HER2, PIK3CA, deletion of tu-
mor suppressor genes PTEN with K-ras transformation, NF1,
RAD51B can also be found in chemoresistant serous ovarian defects,
and common with mucous and clear cell ovarian tumor types
[65e67]. In addition to receptors for estrogens, progesterone and
androgen those gene defects can be used as markers in ovarian
carcinomas [69,70]. Furthermore, BRCA1 and BRCA2 gene defects
that include loss of their promoter methylation, can account only
for 3e13% of all resistant ovarian cancers [69,71]. They can co-
associate with non-polyposis colorectal cancer Lynch syndrome,
mutations of mismatch repair [NMR] genes [72]. Finally, out that of
Fig. 10. AeG: This pane is a series of TEM aspects of VC: VK3-treated endometrioid ovarian carcinoma (MDAH 2774) cells and conﬁrming their LM injuries with cell morphology
changes including nuclei (A, C, and G) and cytoplasmic alterations leading to tumor cell autoschizis with cell distortions and autoschizic cell death. In A: a nucleus demonstrates
compaction of the nucleolus into three masses of granular components (G < B <A)>. In C the nucleus undergoes karyorrhexis with fragmented chromatin. The self-excising
cytoplasm cuts are highly contrasted with innumerable ribonucleoproteins and glycogen granules (shown in C -E regions enlarged). The approximate regions of auto-cuts are
indicated by small curved arrows throughout the micrographs. They contain many aligned or grouped numerous vacuoles out of endomembrane (endoplasm) and mitochondria
damaged by the pro-oxidant, anticancer treatment. Scales in all the micrographs equal 1 mm and in the one of enlarged pieces of CeDeE equals 200 nm.
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a majority of ﬁrst surgeries while ATM, ATR, TOP2A and TOP2B
were mutated in the entire data set. At second surgery, mutation
data clustered patients in two groups characterized by different
mutational proﬁles in genes associated with HR, PI3K, miRNA
biogenesis and signal transduction [73].
4.3. The strategy of pro-oxidant treatment used against tumor cells
Initially conceived by Taper and collaborators [21,22,24,74e79]
the pro-oxidant strategy against cancer cells is to favor a dere-
pression of some part of the metabolome (macromolecular
component, such as HP [69]), and enzyme repression or inhibition
during activities in carcinogenesis (e.g. DNases and RNases, per-
oxidative and catalatic, NADPH reductase, etc). Such unfavorable
changes in the metabolome of tumors allow for a potent cytotoxic
activities because the tumor cells are known to have very low
catalatic and peroxidase activities [80e84]. Hence a new thera-
peutic strategy of an alternative and complementary cytotoxic ac-
tions of a mixture of two natural products where the data have
been provided by the aforementioned results and those discussed
in the earliest published data [13,17e21].
4.4. VC: VK3 treatment aka Apatone
®
Taper and coworkers demonstrated that a co-administration of
sodium ascorbate (vitamin C or VC) and 2-methyl-1,4-
naphthoquinone (vitamin K3 or VK3) to a variety of carcinoma
cell lines and xenotransplanted tumors in a VC: VK3 ratio of 100:1
resulted in equivalent antineoplastic activity at concentrations that
were 10e50 times lower than when either vitamin was adminis-
tered alone [21,22,24,74e79,85,86]. Because tumors exhibit char-
acteristic loss of some DNases and RNase activities [89,90], Taper's
group further they hypothesized that these enzymes could be
reactivated by a number of agents, including vitamins C and K3 and,
in the course of many published studies, showed that selective and
sequential reactivation of DNase I by VK3 (within 1 h after treat-
ment) and DNase II by VC (3e4 h after treatment) when both vi-
tamins were administered in combination, resulted in synergistic
degradation of DNA and tumor regression [21,22,24,74e79]. These
anticancer activities were caused by the redox cycling of the vita-
mins in the mechanism of action of the vitamin combination
causing an oxidative stress. The induced production of reactive
oxygen species (ROS) accompanied by a classical, concomitant
damage to membranes and other lipid-rich cell structures, along
with the oxidation of sulfhydryl (-SH) groups and depletion of
reduced glutathione [87,88,90,91] produced irreversible damage in
the cancer cells which leads to autoschizis [13e19,21,92]. These
anticancer activities were illustrated in other cell lines and in
xenotransplanted tumors [21,87,88,94,95].
4.5. The antiproliferative activity of the VC: VK3 combination
The vitamin combination has been shown to exhibit synergistic
in vitro antiproliferative activity against liver, endometrial, oral
epidermoid, breast and awide variety of human urologic tumor cell
lines as well as in vivo against liver and prostate cancer
[21,22,24,74e79]. At least a portion of this activity may be due to
cell cycle arrest at G1/S and G2/M [94,95]. Multinucleate cells
observed throughout the cultivation samples suggest disruptions of
cell cycle at both stages aforementioned either through prophase or
anaphase blocks. Additional cytotoxic activity is related to an
increased rate of redox cycling and ROS production caused by the
ability of VC to facilitate the single electron cycling of VK3 [96e99].
Because of the redox cycling and ROS production of the vitamincombination, the homeostasis of the MDAH cells is more rapidly
disturbed and the cytological insults are greater than with either
vitamin alone.
Finally, the spread DNA pattern following electrophoresis
(Fig. 2B) suggests that DNAdegradationwas not part of an apoptotic
process. While these results are consistent with the sequential
reactivation of both DNase I and II [21], they do not preclude the
possibility that the decreased Feulgen staining may be related to
ROS-induced DNA damage stemming from an increased rate of
redox cycling. Therefore, additional experiments must be per-
formed to unequivocally determine the trigger(s) and origin(s) of
the molecular mechanism responsible for this DNA degradation.
In previous in vivo studies, sub-therapeutic doses of VC and VK3
were administered to the test animals so that the vitamins only
exerted their cytotoxic effects when both vitamins were present
together in the tumor cells. Under these conditions, selective and
sequential reactivation of DNase I by VK3 and DNase II by VC in the
vitamin combination, resulted in synergistic degradation of DNA
and tumor regression [21,24,75,76]. To simulate these conditions
in vitro and to ensure that we did not miss the window of activity
and synergism, the vitamins were administered at concentrations
where one vitamin alone (VC) was active, while the other vitamin
(VK3) was only marginally active. MTT cytotoxicity assays with the
vitamins [23,92,93] produced CD50 values of 1528 mM for vitamin C,
41.8 mM for vitamin K3 and 165 mM/1.65 mM for the VC: VK3 com-
bination. Therefore, the dose of VC used in the current study
(2032 mM) was slightly greater than CD50 value of 1528 mM. To
maintain VC: VK3 ratio of 100:1, 20.32 mM VK3 was used. Since the
CD50 of VK3 is 41.8 mMand the dose of VK3 employed in this study is
20.32 mM, the activity of the VK3 is expected to be much less than
the activity of the VC. Indeed, VC treatment produced a signiﬁcant
decrease in Feulgen staining of DNA, while VK3 treatment had little
effect on Feulgen staining. However, when VK3 is administered
with VC, there was an additional signiﬁcant decrease in Feulgen
staining of DNA beyond what was observed for VC alone.
The intracellular mechanisms of favorable penetration in the
tumor cells by the anticancer drug mixture is the possession of
GLUT-1 expression in most ovarian tumors, including the endo-
metrioid ones, because ascorbate can use this channel to accumu-
late in the tumor cells [100], especially after oxidative stresses
created by a menadione or VK3 fast and ﬁrst activity [21], that is
why an apparent antioxidant such as ascorbate, becomes an
oxidative species [90].
These results demonstrate that the CD50 value of the vitamin
combination for the human foreskin ﬁbroblasts (MHRF) ﬁbroblasts
was 6-fold greater than CD50 value of the vitamin combination for
the MDAH cells. These results agree with those of Zhang and co-
workers [101] who showed that while VC and VK3 induced syner-
gistic cytotoxicity against ﬁbroblasts as well as tumor cells, ﬁbro-
blasts were not as sensitive to the cytotoxic effects of the vitamins
as the tumor cells. In addition, in the current study, the FIC values
for theMDAH cells and theMHRF cells are nearly identical (0.147 vs.
0.145). These results suggest that once cytotoxic doses are reached
in non-tumor cells, the vitamins exhibit the same type of syner-
gistic toxicity observed in tumor cells. Since the CD50 value for VC:
VK3 treated MHRF cells was 1000 mM: 10.0 mM and the vitamins
were administered at a dose of 2032 mM: 20.32 mM, one would
expect to see some cytotoxicity in the ﬁbroblasts. In fact, a low
molecular weight smear is seen in Fig. 2B when total DNA of MHRF
cells was examined.
The in vitro results suggest a very narrow therapeutic window
for the vitamin combination. However, the results of in vivo studies
demonstrated that administration of clinically attainable doses of
oral vitamins could signiﬁcantly reduce the growth rate of solid
prostate cancer tumors in nude mice any signiﬁcant bone marrow
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organs [21,24].
4.6. Morphologic changes of tumor cells
The combined anticancer treatment resulted in showing by light
microscopy techniques that MDAH cells have decreased their
population, modiﬁed their general morphology through some
likely defects in their superﬁcial actin networks [13e17,102], and
deep cytoskeleton of cytokeratin ﬁlaments and have also signiﬁ-
cantly reduced their size through self-excisions or autoschizis.
Some of these injurious defects have also favored cell death
through these damages as one also found nuclear changes that
were already described when tumor cells underwent such cell
death by autoschizis [13e20]. The least of all can be found as MDAH
cells depicted a progressive but also signiﬁcant DNA disintegration
caused by the combined treatment strongly supporting the reac-
tivation of DNAses favored by the treatment as it was supported for
prostate and bladder carcinoma cells in vitro [13,19,92] and, in vivo,
as xenotransplants [21,22,24]. Observing some large, bi-nucleated
MDAH cells as a result of the combined treatment can also vali-
date the anticancer treatment because our earliest data on other
carcinoma cells, similarly treated, showed after ﬂow cytometry that
a blocks occurred in G1-S and G2-M phases backing up previous
observations [94,95].
The ﬁne structural micrographs also substantiate the injurious
events induced by the treatment that favored auto- or self-
excisions of the highly contrasted cytoplasm containing no organ-
elles. Along with these events nuclei also depicted nucleoli without
their associated chromatin. It is because the chromatin component
withdrew from them and reduced those nucleoli into compact, ri-
bonucleoproteinsmasses [13e20] as they also undergo a signiﬁcant
DNA degradation as noted by the diminution of the Feulgen stain
contrast [18]. Simultaneously ﬁbrillarin pattern has been altered
[103]. This is similar to other carcinoma cells treated by this pro-
oxidant mixture [92,104,105]. TEM views indicated that the treat-
ment with VC: VK3 favored injuries inﬂicted by ROS stresses on
membranes and also included vacuolization and autophagic events
[13e17,104,105] The perikaryal zones demonstrate only remnants
of most organelles degraded through leaking lysosomes
[92,105e108]. Meanwhile the most intriguing and interesting
phenomenon already noticed in our earliest data are the auto- or
self-excising events [13e20] that seemed to have deemed a
grouping of these vacuoles at the edges of those perikaryal zones. In
those areas, as shown inmany illustrations, small SER/RER vacuoles
(25e200 nm diam) appeared to join up, merge and create a
weakness zone out of which piece(s) of cytoplasm can excised.
Similar amalgamation of such event can also further continue to
reduce cell size and with nuclear degradation. This is shown in
other cell lines studied from which we derived the name of cell
injury that progresses into a new mode of cell death, different than
apoptosis, not only by its morphology but also its biochemical
characteristics [13e20,105].
These auto- or self-excising events can be suggested by SEM
collected data where pieces of cells or corpses scattered the inter-
cellular spaces in all of our cell lines examined after the same
treatment. This was also seen in human prostate carcinoma grafted
in mice [21,92].
4.6.1. DNA degradation as karyolytic damages of MDAH2774
Ten DNA optic density measurements of MDAH 2774 cells were
obtained within each of 3 independent sites on the microscopic
preparations for each of the four conditions yielding 30 observa-
tions per experimental condition (Fig. 7). The analysis of variance
modeled the nesting of measurement within site (mixed modeling)so that there were three primary units of analysis (sites) for each
condition. A signiﬁcance level of 0.05 was used for the interaction
test. This was also reviewed in previous reports [13e20].
Total DNA extracted from MDAH-treated cells and human
foreskin ﬁbroblasts (MHRF) following Sham treatment or 4 h
treatment with the vitamin combination. The DNA was then
resolved electrophoretically as shown in Fig. 8. Lanes 2 and 3
contain the DNA of VC: VK3-treated (VCK) and sham-treated (CNT)
MHRF cells. The DNA from the Sham-treated MHRF cells appears as
a single high molecular weight band slightly below the well in
which it was loaded. Conversely, the DNA from VC: VK3-treated
MHRF cells appear as a low molecular weight smear at or below
200 bases. The DNA from Sham-treated MDAH cells also appears as
a single high molecular weight band slightly below the well in
which it was loaded, while the DNA from vitamin treated MDAH
cells exhibits a spread pattern. The absence of laddering in
the vitamin-treated lanes strongly suggests that VC: VK3-induced
cell death is not apoptosis. This indicates that tumor cells
are damaged ﬁrst with a sequence indicated as follows: VC:
VK3 > VK3 > VC > Sham treatment. This sequence can be veriﬁed by
the aforementioned experiments. A newmode of cell death by self-
excising, not just cytoplasm but also the desintegration of DNA had
also occurred
Here one evidenced with morphology and histochemistry as
well as biochemistry techniques that one of the common ovarian
carcinomas as other carcinomas, exposed to a pro-oxidant treat-
ment of one-, two- and three-hour to a combined ascorbate:
menadione mixture die mainly through autoschizis without
damaging normal cells.
4.6.2. Autoschizis cell death
This mode of induced cancer cells is different that apoptosis as it
is not programmed. Data showed that tumor cells die out of nu-
cleases' reactivation accompanying by unprotected peroxidation
with lysosomal damages leaking cathepsins to nucleus structures
[105]. This mode of cell death has been characterized through
several techniques that included biochemistry following the ﬁrst
observationsmade in 1995 [109] and, in the following years, similar
data accumulated on human bladder, ovarian, prostate and murine
prostate carcinomas [13e19,21,93e95,104,109] as well as reviewed
in three book Chapters [20,92], including a more recent, [110], in
press].
Autoschizis exhibits a unique set of morphological and bio-
molecular alterations that distinguish it from apoptosis and oncosis
as deﬁned in previous studies and surveys [13,14,19,20,92,104,106].
Speciﬁcally, in bladder and prostate cancer cells, cytoplasmic self-
excisions and the associated nuclear changes result in the dimi-
nution of cell size, the disappearance of chromatin from nucleolus
and nucleoplasm and subsequent nucleolar compaction and frag-
mentation during karyorrhexis and karyolysis. During these events,
DNA is degraded in a random fashion similar to that occurring
during necrosis.
Autoschizis, a new form of cell death, and histochemical changes
suggests a potentially important ovarian cancer treatment: several
trends are evident from this study. First, there is a signiﬁcant
decrease in the viable adherent cell population in the sequence
Sham-Control>VC> VK3>VC: VK3. Second, cell diameters decrease
from 15-35 mm to 7e12 mm in the same sequence. Third, extreme
pleiomorphism, cell damage, and progressive self-morsellation re-
sults from vitamin treatment in the order VC:
VK3 > VK3 > VC > Sham-Control. Ultrastructural damages appear to
correlate qualitatively with decreases in Feulgen staining (DNA
content), self-morsellation and DNA damage in the sequence VC:
VK3 > VC > VK3 > Sham-Control. Fourth, plasma membrane
and intracellular membrane damage, extreme mitochondrial
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ensues after vitamin treatment in the sequence VC:
VK3 > VK3 > VC > Sham-Control. Fifth, progressive nuclear changes
(from redistribution of euchromatin producing a thinmargin of DNA
along the nuclear envelope and dissolution) and nucleolar changes
(from branching to compaction, segregation and crystallization of
the ribonucleoproteins into a single round body) are seen following
vitamin administration in the sequence VC: VK3 > VK3> VC> Sham-
Control. These injurious processes contribute to cell death by auto-
schizis which cell death after treatment by Apatone® or an appro-
priate mixture of VC: VK3 is, for MDAH 2774 cells, more frequent
than apoptosis or oncotic necrosis [15e18].Fig. 11. Diagrammatic representation of a tumor cell undergoing autoschizic cell death.5. Conclusion
As a combined pro-oxidant the cytotoxic capabilities of the
vitamin mixture can kill tumor cells primarily through a newmode
of cell death, autoschizis, a process causing irreversible nuclear and
cytoplasm injuries that are summarized in Fig. 11.
Altogether, it is quite interesting and important to further
enable detecting genetic markers as soon as possible in blood tests
among these ovarian tumor types as early as possible because the
tumor metabolomics heterogeneity may be important to treat pa-
tients with a more ‘personalized treatment’ [68,73]. Even though
some genetic efforts have been not so promising [111], new po-
tential successes could be involvingmicroRNAs [112]. However, and
in the meantime, a safe and inexpensive anticancer treatment is
still lacking. That is why one can propose that, based on the data
submitted, along with those of our late colleague [24], Apatone®
treatment may, in the meantime, assists in several stages of patient
treatment.
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